ICNMD 2024

Confirmed Exhibitors

Confirmed Exhibitors

We would like to thank the following companies for their support.

EXHIBITORS

argenx | Booth #201
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. (www.argenx.com)

Biogen | Booth #205
At Biogen, we care deeply about making a difference and we are humbled by the opportunity to change lives. Our 40-plus years of scientific expertise in neuroscience have helped to bring options to the lives of people living with neurological and neurodegenerative diseases, including the first-ever disease-modifying therapy for spinal muscular atrophy (SMA) approved for Australia and New Zealand, and through our portfolio of innovative treatment options for multiple sclerosis (MS).

We are committed to working with communities that represent the people we serve, to provide meaningful support beyond our medicines. For over 15 years, we have partnered with the Australian and New Zealand Association of Neurologists (ANZAN) because we recognise the importance of promoting the highest standards of clinical neurology. In addition, we realise the necessity for continued professional healthcare education for the medical community, to best serve people living with serious neurological conditions. Biogen is proud to once again partner with ANZAN in 2024. Learn more at www.biogen.com.au

F. Hoffmann-La Roche Ltd. | Booth#305
Roche is investigating more than a dozen medicines for neurological disorders, including spinal muscular atrophy, multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
Learn more at www.roche.com.

IOS Press
Explore the IOS Press Neurodegenerative Disorders Journals Collection at ICNMD.Dive into the forefront of neurodegenerative disease research with the IOS Press Neurodegenerative Disorders Journals Collection. This comprehensive collection encompasses premier, peer-reviewed journals dedicated to pushing the boundaries of our understanding, improving patient care, and paving the way towards a cure for neurodegenerative disorders.(www.iospress.com/neurodegen)

Janssen Asia Pacific| Booth #200

Janssen is now Johnson & Johnson Innovative Medicine. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal.
Learn more at www.janssen.com.


Janssen Australia, Ltd., a Johnson & Johnson company
Janssen Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd.

Novartis | Booth #404
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Learn more at www.novartis.com.

PTC Therapeutics | Booth #304
PTC Therapeutics is a science-driven, global biopharmaceutical company focused on the discovery and development of clinically differentiated medicines that provide benefits to patients with rare disorders. Our mission is to provide access to best-in-class treatments for patients with little to no treatment options. Learn more about PTC at www.ptcbio.com.
Sarepta Therapeutics | Booth #204
Sarepta Therapeutics is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Our focus is on Duchenne and limb-girdle muscular dystrophies, and we have 40+ programs in development across 3 technologies – gene therapy, RNA and gene editing. (www.sarepta.com)

Takeda | Booth #209
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. (takeda.com)

UCB | Booth #301
UCB, headquartered in Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. (www.ucb.com) 

MGBase Registry
MGBase is the first global, observational registry dedicated to collecting de-identified data from patients diagnosed with myasthenia gravis. It provides a free research platform for clinicians to evaluate real-world outcomes data through collaborative, international research with the aim to advance myasthenia research and improve quality of patient care and outcomes.
Learn more at www.mgbase.org.